Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017.
Gilead’s portfolio As discussed previously, Gilead Sciences’ (GILD) portfolio includes antiviral drugs and other drugs. Whereas its antiviral products include those for hepatitis C, HIV, and hepatitis B infections, its other drugs include oncology, cardiovascular, inflammation, respiratory, and other products. HIV and hepatitis B products The above chart compares revenue for key HIV and hepatitis B products, which include […]
Harvoni is the top-selling drug in Gilead Sciences’ (GILD) portfolio. The drug is used for the treatment of genotype-1 hepatitis C virus (or HCV) infection.
In 1Q17, Ionis Pharmaceuticals reported EPS (earnings per share) of $0.03 on revenue of $110.3 million, compared with EPS of -$0.52 on revenue of $36.9 million in 1Q16. In this series, we’ll look at its valuation since 1Q17.
While Neurocrine Biosciences (NBIX) invented and developed Elagolix until Phase 2 trials, it is currently being tested in Phase 3 trials by AbbVie (ABBV).
Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.
After the UK’s decision to withdraw from the EU, a sudden shock hit global markets on June 24. BioMarin lost ~11% of its value in the subsequent two days.
Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. For oncology, its product portfolio includes targeted therapies as well as immunotherapies.
Vimizim contributed 26% to the top line of BioMarin Pharmaceutical in 2015. Meanwhile, the number of patients on Vimizim rose by 10% during 4Q15 over 3Q15.
BioMarin holds three drugs in its portfolio indicated for different types of mucopolysaccharidoses disorders. They are Vimizim, Naglazyme, and Aldurazyme.
PBE’s biotechnology subsector is trading below its 100-day moving average by 3.0%, but above it 20-day and 50-day averages by 1.3% and 4.0%, respectively.
The PowerShares Dynamic Pharmaceuticals Portfolio ETF (PJP) is a smart beta fund that tracks the performance of the Dynamic Pharmaceutical Intellidex Index.
